• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

    1.845 +0.005 (+0.27%)
    Streaming Delayed Price Updated: 11:09 AM EDT, Jun 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 778,437
    Open 1.850
    Bid (Size) 1.840 (2,500)
    Ask (Size) 1.850 (2,500)
    Prev. Close 1.840
    Today's Range 1.835 - 1.920
    52wk Range 1.040 - 3.535
    Shares Outstanding 60,705,391
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears ↗
    Caribou Biosciences (NASDAQ:CRBU) Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate... 
    Via MarketBeat
    News headline image
    Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
    From Caribou Biosciences, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +16.0%
    +16.0%
    1 Month
    -9.1%
    -9.1%
    3 Month
    -6.3%
    -6.3%
    6 Month
    -2.4%
    -2.4%
    1 Year
    +45.3%
    +45.3%

    More News

    Read More
    News headline image
    Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments ↗
    Via Stocktwits
    News headline image
    Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Caribou Biosciences to Participate in Upcoming Investor Conferences
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Caribou Biosciences to Participate in Upcoming Investor Conferences
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Aprea Therapeutics (Nasdaq: APRE) Transforms Cutting-Edge Science into Next-Generation Cancer Therapies – More Stocks Inside
    Via AB Newswire
    Topics Artificial Intelligence
    News headline image
    Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today? ↗
    Via Benzinga
    News headline image
    Gapping stocks in Monday's session ↗
    Via Chartmill
    News headline image
    Discover the top movers in Monday's pre-market session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket ↗
    Via Benzinga
    News headline image
    Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma
    From Caribou Biosciences, Inc.
    Via GlobeNewswire
    News headline image
    Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
    Via MarketMinute
    Topics Artificial Intelligence Climate Change Economy

    Frequently Asked Questions

    Is Caribou Biosciences, Inc. - Common Stock publicly traded?
    Yes, Caribou Biosciences, Inc. - Common Stock is publicly traded.
    What exchange does Caribou Biosciences, Inc. - Common Stock trade on?
    Caribou Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Caribou Biosciences, Inc. - Common Stock?
    The ticker symbol for Caribou Biosciences, Inc. - Common Stock is CRBU on the Nasdaq Stock Market
    What is the current price of Caribou Biosciences, Inc. - Common Stock?
    The current price of Caribou Biosciences, Inc. - Common Stock is 1.845
    When was Caribou Biosciences, Inc. - Common Stock last traded?
    The last trade of Caribou Biosciences, Inc. - Common Stock was at 06/09/26 11:09 AM ET
    What is the market capitalization of Caribou Biosciences, Inc. - Common Stock?
    The market capitalization of Caribou Biosciences, Inc. - Common Stock is 112.00M
    How many shares of Caribou Biosciences, Inc. - Common Stock are outstanding?
    Caribou Biosciences, Inc. - Common Stock has 112M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.